Scynexis Inc (SCYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Scynexis Inc (SCYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH122661D
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company provides pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis C (HCV); SCYX-7158, is used for sleeping sickness; SCY-641, is for human health, among others. Its SCY-078 is a chemical class of glucan synthase inhibitors that blocks target in infectious fungi by interfering with the assembly of the fungal cell wall and prevents the growth of fungal species. Scynexis provides its drug pipeline solutions to pharmaceutical, healthcare and life sciences companies, among others. The company develops products by using technology platforms such as enfumafungin platform, cyclophilin platform and calcineurin platform, among others. Scynexis is headquartered in Jersey City, New Jersey, the US.

Scynexis Inc (SCYX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Scynexis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Scynexis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Scynexis Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Scynexis Raises Additional USD 6 Million In Venture Financing 11

Partnerships 12

Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 12

Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 13

Licensing Agreements 14

Scynexis Enters into Licensing Agreement with Waterstone Pharma for SCY-635 14

Equity Offering 15

SCYNEXIS to Raise up to USD25 in Public Offering of Shares 15

Scynexis Raises USD30 Million in Public Offering of Shares and Warrants 16

Scynexis Raises USD22.5 million in Public Offering of Shares and Warrants 18

Scynexis Raises USD41 Million in Public Offering of Shares 20

Scynexis Raises USD62 Million in IPO 22

Asset Transactions 24

Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 24

Avista Pharma Acquires Contract Services Business from Scynexis 25

Accelrys Acquires Hit Explorer Operating System From Scynexis 27

Scynexis Inc-Key Competitors 28

Scynexis Inc-Key Employees 29

Scynexis Inc-Locations And Subsidiaries 30

Head Office 30

Recent Developments 31

Financial Announcements 31

Aug 09, 2018: SCYNEXIS announces second quarter 2018 financial results 31

May 08, 2018: SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update 33

Mar 13, 2018: SCYNEXIS Reports Full Year 2017 Financial Results 35

Nov 07, 2017: SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update 37

Aug 08, 2017: SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update 39

May 08, 2017: SCYNEXIS Reports First Quarter 2017 Financial Results 41

May 08, 2017: SCYNEXIS Q1 net loss decreases 42

Mar 13, 2017: SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update 43

Corporate Communications 45

Jan 26, 2017: SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors 45

Product News 46

10/05/2017: SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017 46

07/18/2018: The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078 47

06/27/2018: SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting 48

06/15/2017: New Study Further Demonstrates In Vitro Activity of SCYNEXIS' Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains 49

06/14/2018: SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018 50

06/11/2018: SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 51

06/05/2017: Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078 52

05/24/2018: SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018 53

04/21/2017: SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID 54

04/10/2018: SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease 55

Product Approvals 56

Mar 02, 2017: SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDAs request 56

Clinical Trials 57

Jul 10, 2018: SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis 57

Jun 06, 2018: SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology 59

May 01, 2018: SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC 60

Apr 23, 2018: SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis 61

Mar 20, 2018: SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 62

Feb 01, 2018: SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018 63

Jan 04, 2018: SCYNEXIS Provides Corporate and SCY-078 Pipeline Update 64

Sep 27, 2017: SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 66

Aug 14, 2017: SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting 67

Aug 03, 2017: SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis 68

May 24, 2017: Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections 69

May 11, 2017: Potent in vitro Activity of SCYNEXIS SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention 71

May 08, 2017: SCYNEXIS Provides Update on IV Formulation Development Status 73

Apr 25, 2017: Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS' Lead Anti-infective Candidate SCY-078 74

Apr 12, 2017: SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases 76

Feb 24, 2017: First Systematic Study of Deadly, Antibiotic-Resistant Fungus Reported 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79

List of Figures

Scynexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Scynexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Scynexis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Scynexis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Scynexis Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Scynexis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Scynexis Raises Additional USD 6 Million In Venture Financing 11

Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 12

Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 13

Scynexis Enters into Licensing Agreement with Waterstone Pharma for SCY-635 14

SCYNEXIS to Raise up to USD25 in Public Offering of Shares 15

Scynexis Raises USD30 Million in Public Offering of Shares and Warrants 16

Scynexis Raises USD22.5 million in Public Offering of Shares and Warrants 18

Scynexis Raises USD41 Million in Public Offering of Shares 20

Scynexis Raises USD62 Million in IPO 22

Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 24

Avista Pharma Acquires Contract Services Business from Scynexis 25

Accelrys Acquires Hit Explorer Operating System From Scynexis 27

Scynexis Inc, Key Competitors 28

Scynexis Inc, Key Employees 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Scynexis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17745
Site License
USD 500 INR 35490
Corporate User License
USD 750 INR 53235

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com